Association of Fourth Pfizer-BioNTech Vaccine Dose With SARS-CoV-2 Infection

JAMA Network Open


Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.


About The Study: Researchers found that 4-dose recipients of the Pfizer-BioNTech vaccine had a lower risk of acquiring COVID-19 than 3-dose recipients during the peak Omicron variant wave in this study of 29,000 health care workers in Israel.

Authors: Allon E. Moses, M.D., of the Hadassah-Hebrew University Medical Center in Jerusalem, is the corresponding author.



Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.